Use of IL-1beta compounds

US8409576B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Phil Lowe · Basel, CH
• Hermann Gram · Weil am Rhein, DE
• Thomas Jung · Wien, AT
• Timothy Wright · San Diego, US
• Trevor Mundel · Carlisle, US

Key dates

• Filing date: Oct 27, 2011
• Grant date: Apr 2, 2013
• Expiry date: Oct 27, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.